Due to a less favourable outcome in the subscription participation than it expected and the fact that the shares are trading below the offer price, Curasight has decided not to proceed with the rights issue. COB Per Falholt stated that the company is committed to finding alternative financing in order to continue to develop both uTRACE and uTREAT. This is clearly negative news in our view. Curasight has cash runway to end-Q2/24 so new financing needs to be secured in a hurry.

Link to the analysis